Safety of an Infant Formula With Hydrolysed Protein in Term Infants (HASI)

Safety and Suitability of an Infant Formula Manufactured From Extensively Hydrolysed Protein in Healthy Term Infants

A multi-centre, randomised, double-blind, parallel-group, controlled, prospective, non-inferiority intervention clinical trial is performed to assess the safety and suitability of an infant formula manufactured from extensively hydrolysed protein by showing normal growth of healthy term infants during the first 120 days of life with an optional follow up until 180 days of life.

Study Overview

• Status: Completed
• Conditions: Growth
• Intervention / Treatment: Other: Intervention Group: Infant Formula with hydrolyzed protein; Other: Control Group: Infant Formula with intact protein

Detailed Description

Since many years the use of infant formulae manufactured from hydrolysed proteins are recommended for infants at risk for developing allergies if they cannot be exclusively breast-fed. Although the use of such formulae manufactured from hydrolysed protein is legally authorized according to the respective legal framework since many years (currently: Directive 2006/141/EC), the safety of each hydrolysed protein has to be substantiated by additional clinical data according to new legal requirements (Del. Regulation (EU) 2016/127). This study is intended to generate clinical safety data: demonstrating adequate growth of infants fed a formula manufactured from hydrolysed protein in comparison to infants fed a formula manufactured from intact protein. As formula manufactured from hydrolyzed proteins is known to have beneficial effects on gastrointestinal comfort, it is also fed to infants not at risk for developing allergies. Therefore, this study additionally investigates the impact of hydrolysed protein on gastrointestinal tolerance.

• Study Type: Interventional
• Enrollment (Actual): 360
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 13589
    • Evangelisches Waldkrankenhaus Spandau

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 second to 3 weeks (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy male or female term infants until 25 days of age from singleton pregnancies
• Gestational age ≥37+0 weeks until 41+6 weeks
• Birth weight between ≥3rd and ≤97th percentile per gestational age
• Infants whose parent(s) / legally authorized representative(s) have reached the legal age of consent
• Infants whose parent(s) / legally authorized representative(s) are capable of and willing to comply with the protocol and have signed the informed consent form in accordance with legal requirements

• Infant formula group

  • Infants of mothers, who could not breastfeed their healthy newborn babies for reasons not related to this study, or who decided despite the advice on the benefits of breastfeeding to start exclusive formula-feeding within the first 25 days of age of their infant.
  • Parent(s) / legally authorized representative(s) confirm their intention to feed their infant the investigational product as the only source of nutrition from 26 days of age onward through the duration of the main study (until 120 days of age), and agree that no other infant formula, drinks (water, tea, juice,…) or complementary foods will be introduced until the infant reaches the age of 120 days.

• Breastfeeding reference group

  • Infants of mothers, who decided to exclusively breastfeed their infant until at least 120 days of age
  • Parent(s) / legally authorized representative(s) confirm their intention to breastfeed their infant as the only source of nutrition, from 26 days of age onward throughout the duration of the main study (until 120 days of age), and agree that no other infant formula, liquids (water, tea, juice,…) or complementary foods will be introduced until the infant reaches the age of 120 days.

Exclusion Criteria:

• Infants whose biological parents or full siblings have a history of doctor's diagnosed atopic diseases (atopic dermatitis, hay fever, allergic asthma or rhinitis) and have been in medical treatment prior to or at enrolment visit
• Intensive care prior to or at enrolment visit
• Severe acquired or congenital illness, or chromosomal anomalies (if known) in infants that are expected to interfere with normal feed or growth
• Hypo- or hypertrophy <3rd or >97th percentile of birth weight per gestational age
• Infants under (ongoing) antibiotic treatment before or at enrolment visit longer than three days (72 hours)
• Infants requiring infant formula intake other than those specified in the protocol
• Feeding difficulties or infant formula intolerance
• Disease of parents that may have an impact on study conduct or that may have an influence on infant growth and feeding behaviour based on the investigator's opinion
• Recreational drug or alcohol intake by the mother during the last two trimesters of pregnancy
• Infants born to mothers with medical conditions which have an effect on the infants' gastrointestinal tract/ability to be fed and/or growth (e.g. insulin dependent diabetes mellitus)
• Participation in another clinical intervention study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention Group: Infant Formula with hydrolyzed protein; Infants will receive the following infant formula: Infant formula manufactured from extensively hydrolyzed proteins and containing pre- and probiotics.	Other: Intervention Group: Infant Formula with hydrolyzed protein; Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (intervention formula manufactured from extensively hydrolysed whey protein).
Active Comparator: Control Group: Infant Formula with intact protein; Infants will receive the following infant formula: Infant formula manufactured from intact proteins and containing pre- and probiotics.	Other: Control Group: Infant Formula with intact protein; Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (control formula manufactured from intact cow's milk protein).
No Intervention: Breast Fed Group; Exclusively breast milk

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Infant daily weight gain (in g/day) between 30 days and 120 days of age	90 days duration

Collaborators and Investigators

• Sponsor: HiPP GmbH & Co. Vertrieb KG
• Collaborators: Biofortis, Merieux NutriSciences; Waldkrankenhaus Protestant Hospital, Spandau; HungaroTrial
• Investigators: Principal Investigator: Frank Jochum, PD Dr. med., Evangelisches Waldkrankenhaus Spandau, Berlin, Germany

Study record dates

Study Major Dates

• Study Start (Actual): March 16, 2021
• Primary Completion (Actual): August 31, 2021
• Study Completion (Actual): October 27, 2021

Study Registration Dates

• First Submitted: January 29, 2021
• First Submitted That Met QC Criteria: January 29, 2021
• First Posted (Actual): February 3, 2021

Study Record Updates

• Last Update Posted (Actual): November 26, 2021
• Last Update Submitted That Met QC Criteria: November 24, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: Safety; Growth; Infants; Weight Gain; Infant Formula
• Other Study ID Numbers: 508917-2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No